185 related articles for article (PubMed ID: 32063140)
1. Use of denosumab to treat refractory hypercalcemia in a peritoneal dialysis patient with immobilization and tertiary hyperparathyroidism.
Pratt RM; West ML; Tennankore KK
Perit Dial Int; 2020 Jan; 40(1):103-106. PubMed ID: 32063140
[TBL] [Abstract][Full Text] [Related]
2. Denosumab treatment for refractory hypercalcemia in a hemodialysis patient with tertiary hyperparathyroidism.
Zhang P; Yu Y; Gao Y; Yuan G; Zhang J; Wang W
Hemodial Int; 2023 Apr; 27(2):E23-E28. PubMed ID: 36719850
[TBL] [Abstract][Full Text] [Related]
3. Denosumab for the treatment of bisphosphonate resistant hypercalcemia in a hemodialysis patient.
Dahmani O; Sophoclis C; Kebir M; Bouguern D; Sakho A; Demarchi P
Saudi J Kidney Dis Transpl; 2017; 28(1):154-157. PubMed ID: 28098117
[TBL] [Abstract][Full Text] [Related]
4. Control of Refractory Hypercalcemia with Denosumab in a Case of Metastatic Parathyroid Carcinoma.
Çalapkulu M; Gul OO; Cander S; Ersoy C; Erturk E; Sagiroglu MF; Saraydaroglu O
J Coll Physicians Surg Pak; 2020 Jul; 30(7):757-759. PubMed ID: 32811610
[TBL] [Abstract][Full Text] [Related]
5. Denosumab: a new agent in the management of hypercalcemia of malignancy.
Thosani S; Hu MI
Future Oncol; 2015; 11(21):2865-71. PubMed ID: 26403973
[TBL] [Abstract][Full Text] [Related]
6. Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies.
Thongprayoon C; Acharya P; Acharya C; Chenbhanich J; Bathini T; Boonpheng B; Sharma K; Wijarnpreecha K; Ungprasert P; Gonzalez Suarez ML; Cheungpasitporn W
Osteoporos Int; 2018 Aug; 29(8):1737-1745. PubMed ID: 29713798
[TBL] [Abstract][Full Text] [Related]
7. Effects of Denosumab and Calcitriol on Severe Secondary Hyperparathyroidism in Dialysis Patients With Low Bone Mass.
Chen CL; Chen NC; Liang HL; Hsu CY; Chou KJ; Fang HC; Lee PT
J Clin Endocrinol Metab; 2015 Jul; 100(7):2784-92. PubMed ID: 25955225
[TBL] [Abstract][Full Text] [Related]
8. Denosumab is Effective for Controlling Serum Calcium Levels in Patients with Humoral Hypercalcemia of Malignancy Syndrome: A Case Report on Parathyroid Hormone-related Protein-producing Cholangiocarcinoma.
Ashihara N; Nakajima K; Nakamura Y; Kobayashi M; Shirahata K; Maeda C; Uehara T; Gomi D; Ito N
Intern Med; 2016; 55(23):3453-3457. PubMed ID: 27904108
[TBL] [Abstract][Full Text] [Related]
9. Use of high-dose denosumab in the management of immobilization-related hypercalcemia in an end-stage renal disease patient on hemodialysis: A case report and review of the literature.
Zaitoun MF; Al-Alsheikh KA; Elnazer W
Clin Nephrol; 2021 Dec; 96(6):353-356. PubMed ID: 34605398
[TBL] [Abstract][Full Text] [Related]
10. Hypercalcemia upon denosumab withdrawal in primary hyperparathyroidism: a case report and literature review.
Camponovo C; Aubry-Rozier B; Lamy O; Gonzalez Rodriguez E
Osteoporos Int; 2020 Dec; 31(12):2485-2491. PubMed ID: 33057735
[TBL] [Abstract][Full Text] [Related]
11. The emerging role of denosumab in the long-term management of parathyroid carcinoma-related refractory hypercalcemia.
Fountas A; Andrikoula M; Giotaki Z; Limniati C; Tsakiridou E; Tigas S; Tsatsoulis A
Endocr Pract; 2015 May; 21(5):468-73. PubMed ID: 25667369
[TBL] [Abstract][Full Text] [Related]
12. Use of denosumab in a dialysis patient with bone metastases from breast cancer and hepatorenal polycystic disease: a case report.
Quiroga García V; Cirauqui Cirauqui B; Tobey Robaina L; López Sisamon D; Hardy-Werbin M; Blanca AB; Margelí Vila M
Anticancer Drugs; 2016 Jun; 27(5):464-9. PubMed ID: 26813866
[TBL] [Abstract][Full Text] [Related]
13. Reducing the risk of denosumab-induced hypocalcemia in patients with advanced chronic kidney disease: a quality improvement initiative.
Kanagalingam T; Khan T; Sultan N; Cowan A; Thain J; Hoy C; Ledger S; Clemens KK
Arch Osteoporos; 2023 Nov; 18(1):138. PubMed ID: 37985504
[TBL] [Abstract][Full Text] [Related]
14. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
15. Effective long-term management of parathyromatosis-related refractory hypercalcemia with a combination of denosumab and cinacalcet treatment.
Tzotzas T; Goropoulos A; Karras S; Terzaki A; Siolos A; Doumas A; Zaramboukas T; Tigas S
Hormones (Athens); 2022 Mar; 21(1):171-176. PubMed ID: 34993886
[TBL] [Abstract][Full Text] [Related]
16. Impact of denosumab on cardiovascular calcification in patients with secondary hyperparathyroidism undergoing dialysis: a pilot study.
Chen CL; Chen NC; Wu FZ; Wu MT
Osteoporos Int; 2020 Aug; 31(8):1507-1516. PubMed ID: 32246167
[TBL] [Abstract][Full Text] [Related]
17. Elevated levels of circulating fibroblast growth factor 23 with hypercalcemia following discontinuation of denosumab.
Uchida T; Yamaguchi H; Kushima C; Yonekawa T; Nakazato M
Endocr J; 2020 Jan; 67(1):31-35. PubMed ID: 31527321
[TBL] [Abstract][Full Text] [Related]
18. Humoral Hypercalcemia in a Patient with Cholangiocellular Carcinoma - Effective Therapy with Denosumab.
Harsch IA; Konturek PC
Am J Case Rep; 2019 Sep; 20():1325-1330. PubMed ID: 31492829
[TBL] [Abstract][Full Text] [Related]
19. Ectopic parathyroid hormone as a rare aetiology of hypercalcemia with rhabdomyosarcoma: a new treatment strategy with zoledronic acid and Denosumab.
Kilci F; Demirsoy U; Jones JH; Çakır Ö; Çizmecioğlu-Jones FM
J Pediatr Endocrinol Metab; 2022 Aug; 35(8):1107-1112. PubMed ID: 35534911
[TBL] [Abstract][Full Text] [Related]
20. Oral doxercalciferol therapy for secondary hyperparathyroidism in a peritoneal dialysis patient.
Sprague SM; Ho LT
Clin Nephrol; 2002 Aug; 58(2):155-60. PubMed ID: 12227689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
